TABLE 1.
Description and interpretation of the ACCORD-Lipid trial within news articles and biomedical journal articles published in the 15 months after trial publication.
| News | Biomedical Literature | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| All | All | Review | Editorial/Commentary | Original article | Guideline | |
|
| ||||||
| Articles, No. | 67 | 141 | 70 | 42 | 24 | 5 |
| Proportion of article discussing ACCORD-Lipid trial, No. (%) | ||||||
| Sole focus | 21 (31.3%) | 8 (5.7%) | 1 (1.4%) | 7 (16.7%) | 0 (0.0%) | 0 (0.0%) |
|
| ||||||
| Substantial discussion | 28 (41.8%) | 49 (34.8%) | 21 (30.0%) | 19 (45.2%) | 8 (33.3%) | 1 (20.0%) |
|
| ||||||
| Mentions in passing | 18 (26.9%) | 84 (59.6%) | 48 (68.6%) | 16 (38.1%) | 16 (66.6%) | 4 (80.0%) |
|
| ||||||
| Description of fenofibrate effectiveness in ACCORD-Lipid trial, No. (%) | ||||||
| Effective | 11 (16.4%) | 28 (19.9%) | 15 (21.4%) | 4 (9.5%) | 8 (33.3%) | 1 (20.0%) |
|
| ||||||
| Mixed | 36 (53.7%) | 71 (50.4%) | 36 (51.4%) | 20 (47.6%) | 12 (50.0%) | 3 (60.0%) |
|
| ||||||
| Ineffective | 20 (29.9%) | 42 (29.8%) | 19 (27.1%) | 18 (42.9%) | 4 (16.6%) | 1 (20.0%) |
|
| ||||||
| Recommendation for fibrate use in light of discussing ACCORD-Lipid trial, No. (%) | ||||||
| Supportive | 12 (17.9%) | 52 (36.9%) | 30 (42.9%) | 10 (23.8%) | 9 (37.5%) | 3 (60.0%) |
|
| ||||||
| Neutral | 5 (7.5%) | 13 (9.2%) | 5 (7.1%) | 8 (19.1%) | 0 (0.0%) | 0 (0.0%) |
|
| ||||||
| Unsupportive | 6 (9.0%) | 12 (8.5%) | 5 (7.1%) | 5 (11.9%) | 1 (4.2%) | 1 (20.0%) |
|
| ||||||
| No recommendation | 44 (65.7%) | 64 (45.4%) | 30 (42.9%) | 19 (45.2%) | 14 (58.3%) | 1 (20.0%) |